Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $286

Benzinga · 2d ago
Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $281 to $286.